Kairos Pharma Ltd is a clinical-stage biopharmaceutical company... Show more
The RSI Indicator for KAPA moved out of oversold territory on June 04, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 6 similar instances when the indicator left oversold territory. In of the 6 cases the stock moved higher. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on June 17, 2025. You may want to consider a long position or call options on KAPA as a result. In of 14 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KAPA just turned positive on June 09, 2025. Looking at past instances where KAPA's MACD turned positive, the stock continued to rise in of 5 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for KAPA crossed bullishly above the 50-day moving average on July 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KAPA advanced for three days, in of 18 cases, the price rose further within the following month. The odds of a continued upward trend are .
KAPA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 2 cases where KAPA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 2 cases where KAPA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
KAPA moved below its 50-day moving average on July 03, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KAPA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.538) is normal, around the industry mean (16.672). P/E Ratio (0.000) is within average values for comparable stocks, (58.456). KAPA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (269.644).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. KAPA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KAPA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology